Cosmo gets U.S. approval for agent aimed at easing polyp removal

[September 04, 2015]  ZURICH (Reuters) - Cosmo Pharmaceuticals SA said on Friday that the U.S. Food and Drug Administration has given marketing authorization for SIC 8000, a product used in gastrointestinal tract procedures.

Cosmo said SIC 8000 lifts mucous membranes in the esophagus, stomach, small and large intestines and other organs during removal of things such as polyps.

Its shares, which had been suspended on the Swiss stock exchange, resume trading at 0935 GMT, the exchange said.

(Reporting by John Miller; Editing by Michael Shields)

[© 2015 Thomson Reuters. All rights reserved.]

Copyright 2015 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.